This study evaluates mucositis and other oral symptoms in patients undergoing photobiomodulation in patients undergoing hematopoietic stem cell transplantation.
PRIMARY OBJECTIVE: I. Examine mucositis severity, oral pain, taste changes, and xerostomia in patients undergoing PBM, a new standard of care for oral mucositis. OUTLINE: This is an observational study. Participants are assigned to 1 of 2 groups. GROUP I: Patients have their medical records reviewed on study. GROUP II: Nurses complete surveys on study.
Study Type
OBSERVATIONAL
Enrollment
6
Non-interventional study
City of Hope Medical Center
Duarte, California, United States
Mucositis according to the World Health Organization (WHO) Scale
WHO scale is a combined patient-reported and clinician assessed rating scale that ranges from 0 ( no oral mucositis) to IV (Life threatening mucosistis).
Time frame: Up to 22 days or until discharge, whichever came first
Average oral pain
Patient is asked to rate their pain on a 0 - 10 scale with 0 being no pain and 10 being the worst possible pain.
Time frame: Up to 22 days or until discharge, whichever came first
Taste
Taste according to the Chemotherapy Induced Taste Alteration Scale (CiTAS) which is an 18-item scale that measures four dimensions of taste: decline in basic taste, discomfort, phantogeusia and parageusia, and general taste alterations. Items are stated on a Likert scale 1 - 5 (where 1 = no difficulty or absence of the disturbance and 5 = maximum difficulty or disturbance.
Time frame: Up to 22 days or until discharge, whichever came first
Xerostomia
Xerostomia severity (0-10 scale)
Time frame: Up to 22 days or until discharge, whichever came first
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.